Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $5.1 million.

  • Fortress Biotech's Treasury Shares rose 18519.89% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 18519.89%. This contributed to the annual value of $4.4 million for FY2024, which is 11360.09% up from last year.
  • As of Q1 2020, Fortress Biotech's Treasury Shares stood at $70000.0.
  • In the past 5 years, Fortress Biotech's Treasury Shares ranged from a high of $23.0 million in Q1 2023 and a low of $1.4 million during Q4 2022
  • For the 5-year period, Fortress Biotech's Treasury Shares averaged around $11.1 million, with its median value being $5.7 million (2025).
  • As far as peak fluctuations go, Fortress Biotech's Treasury Shares skyrocketed by 36865026.0% in 2021, and later plummeted by 9283.18% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's Treasury Shares stood at $18.1 million in 2021, then tumbled by 92.41% to $1.4 million in 2022, then soared by 50.86% to $2.1 million in 2023, then soared by 113.6% to $4.4 million in 2024, then rose by 15.91% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $5.7 million for Q2 2025, and $5.5 million during Q1 2025.